- ISIN
- US98887Q1040
- CUSIP
- 98887Q104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 20, 2017
Highlights
- Market Cap
- $1.90B
- Enterprise Value
- $1.70B
- EPS (TTM)
- -$1.62
- Total Revenue (TTM)
- $453.28M
- Gross Profit (TTM)
- $262.53M
- EBITDA (TTM)
- -$183.84M
- Year Range
- $15.96 - $44.34
- Target Price
- $35.00
- ROA (TTM)
- -16.26%
- ROE (TTM)
- -26.91%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ZLAB Performance Chart
Zai Lab Limited (ZLAB) is down 2.8% since the beginning of the year. At $17 per share, ZLAB is trading 61.3% below its 52-week high of $44. Investors who bought $1,000 worth of ZLAB shares 5 years ago would now be looking at an investment worth $97.
Loading charts...
Returns By Period
Zai Lab Limited (ZLAB) has returned -2.78% so far this year and -44.91% over the past 12 months.
Zai Lab Limited
- 1D
- 0.35%
- 1M
- -19.18%
- YTD
- -2.78%
- 6M
- -13.16%
- 1Y
- -44.91%
- 3Y*
- -21.68%
- 5Y*
- -37.25%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
ZLAB Monthly Returns History
Based on dividend-adjusted daily data since Sep 20, 2017, ZLAB's average daily return is +0.07%, while the average monthly return is +0.93%. At this rate, an investment would double in approximately 6.2 years.
Historically, 47% of months were positive and 53% were negative. The best month was Nov 2022 with a return of +73.1%, while the worst month was Oct 2022 at -34.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ZLAB closed higher 49% of trading days. The best single day was Jan 5, 2023 with a return of +41.8%, while the worst single day was Mar 3, 2022 at -20.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.90% | 15.78% | -2.13% | 15.05% | -18.25% | -3.05% | -2.78% | ||||||
| 2025 | 3.82% | 27.40% | 4.33% | -12.31% | -4.89% | 16.03% | 8.09% | -12.43% | 2.39% | -22.90% | -21.89% | -13.57% | -32.65% |
| 2024 | -21.08% | -2.74% | -23.64% | -1.37% | 12.53% | -2.53% | 9.81% | 4.78% | 21.06% | 25.19% | -4.53% | -9.22% | -4.17% |
| 2023 | 37.26% | -11.84% | -10.47% | 5.17% | -7.12% | -14.65% | 8.40% | -15.27% | -4.55% | 3.66% | 8.29% | 0.15% | -10.98% |
| 2022 | -20.97% | 10.13% | -19.60% | -9.14% | -27.18% | 19.18% | 16.87% | 14.01% | -25.99% | -34.85% | 73.07% | -20.38% | -51.15% |
| 2021 | 18.27% | -7.84% | -9.55% | 24.57% | 6.89% | -0.38% | -18.29% | -0.08% | -27.07% | -0.94% | -33.67% | -9.24% | -53.56% |
Benchmark Metrics
Zai Lab Limited has an annualized alpha of 1.35%, beta of 1.09, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since September 21, 2017.
- This stock participated in 77.12% of S&P 500 Index downside but only 18.86% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 1.35%
- Beta
- 1.09
- R²
- 0.09
- Upside Capture
- 18.86%
- Downside Capture
- 77.12%
Return for Risk
Risk / Return Rank
ZLAB ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Zai Lab Limited (ZLAB) and compare them to S&P 500 Index.
| ZLAB | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.81 | 2.39 | -3.20 |
Sortino ratioReturn per unit of downside risk | -1.13 | 3.25 | -4.38 |
Omega ratioGain probability vs. loss probability | 0.87 | 1.43 | -0.56 |
Calmar ratioReturn relative to maximum drawdown | -0.73 | 3.11 | -3.84 |
Martin ratioReturn relative to average drawdown | -1.02 | 14.38 | -15.41 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Zai Lab Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Zai Lab Limited was 92.84%, occurring on Apr 17, 2024. The portfolio has not yet recovered.
The current Zai Lab Limited drawdown is 91.05%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -92.84%Apr 2024 | 3y 2mo | — | 5y 4moJan 2021 - now |
Rate-hike selloffLate 2018 | -56.15%Oct 2018 | 12mo 4d | 8mo 17d | 1y 8moOct 2017 - Jun 2019 |
COVID crash2020 | -29.19%Mar 2020 | 25d | 1mo 2d | 1mo 27dFeb 2020 - Apr 2020 |
2019 bear market2019 | -20.88%Oct 2019 | 2mo 1d | 19d | 2mo 20dAug 2019 - Nov 2019 |
2020 correction2020 | -18.08%Sep 2020 | 2mo 13d | 16d | 2mo 29dJul 2020 - Oct 2020 |
Drawdown Indicators
| ZLAB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.84% | -56.78% | -36.06% |
Max Drawdown (1Y)Largest decline over 1 year | -62.12% | -9.10% | -53.02% |
Max Drawdown (3Y)Largest decline over 3 years | -62.12% | -18.90% | -43.22% |
Max Drawdown (5Y)Largest decline over 5 years | -92.31% | -25.43% | -66.88% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -91.05% | 0.00% | -91.05% |
Average DrawdownAverage peak-to-trough decline | -53.29% | -10.72% | -42.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.01% | 1.97% | +42.04% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Zai Lab Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Zai Lab Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ZLAB relative to other companies in the Biotechnology industry. Currently, ZLAB has a P/S ratio of 4.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ZLAB in comparison with other companies in the Biotechnology industry. Currently, ZLAB has a P/B value of 2.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ZLAB
Add Zai Lab Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ZLAB